NCT06827353View on ClinicalTrials.gov

Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

May 31, 2025

Study Completion Date

September 30, 2025

Conditions
Ovarian Carcinoma
Interventions
DRUG

maintenance therapy with bevacizumab

Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received bevacizumab after chemotherapy.

DRUG

maintenance therapy with niraparib

Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received niraparib after chemotherapy.

Trial Locations (1)

30029

RECRUITING

CHU de Nîmes, Nîmes

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER